Velneperit: Difference between revisions

Revision as of 11:58, 9 February 2025

A chemical compound used in medicine

Velneperit is a chemical compound that has been studied for its potential use in treating various medical conditions. It is known for its role as an inhibitor of the enzyme neutral endopeptidase (NEP), which is involved in the breakdown of certain peptides in the body.

Chemical Properties

Velneperit is classified as a small molecule inhibitor. Its chemical structure allows it to bind to the active site of NEP, thereby preventing the enzyme from interacting with its natural substrates. This inhibition can lead to increased levels of peptides such as enkephalins, which are involved in modulating pain and other physiological processes.

Mechanism of Action

The primary mechanism of action of Velneperit involves the inhibition of neutral endopeptidase. By blocking NEP, Velneperit increases the concentration of peptides that are normally degraded by this enzyme. This can enhance the activity of these peptides, potentially leading to therapeutic effects in conditions where peptide regulation is disrupted.

Potential Therapeutic Uses

Velneperit has been investigated for its potential use in treating conditions such as chronic pain, hypertension, and heart failure. The ability of Velneperit to modulate peptide levels makes it a candidate for these applications, although clinical trials are necessary to fully understand its efficacy and safety.

Research and Development

Research on Velneperit has included preclinical studies and early-phase clinical trials. These studies aim to evaluate the pharmacokinetics, pharmacodynamics, and therapeutic potential of the compound. Results from these studies will determine the future development of Velneperit as a therapeutic agent.

Related Pages

References

@@ Line 1: / Line 1: @@
-'''Velneperit''' is a [[drug]] candidate that was developed by [[Shionogi]] for the treatment of [[obesity]]. It is a selective [[neuropeptide Y]] receptor antagonist, specifically targeting the Y4 subtype.
+{{Short description|A chemical compound used in medicine}}
+{{Use dmy dates|date=October 2023}}
+[[File:Velneperit.svg|thumb|Chemical structure of Velneperit]]
+'''Velneperit''' is a chemical compound that has been studied for its potential use in treating various medical conditions. It is known for its role as an inhibitor of the enzyme [[neutral endopeptidase]] (NEP), which is involved in the breakdown of certain peptides in the body.
-== History ==
+==Chemical Properties==
+Velneperit is classified as a small molecule inhibitor. Its chemical structure allows it to bind to the active site of NEP, thereby preventing the enzyme from interacting with its natural substrates. This inhibition can lead to increased levels of peptides such as [[enkephalins]], which are involved in modulating pain and other physiological processes.
-Velneperit was first synthesized by Shionogi, a Japanese pharmaceutical company, in the early 2000s. The drug was developed as part of a larger effort to find effective treatments for obesity, a growing global health concern.
+==Mechanism of Action==
+The primary mechanism of action of Velneperit involves the inhibition of neutral endopeptidase. By blocking NEP, Velneperit increases the concentration of peptides that are normally degraded by this enzyme. This can enhance the activity of these peptides, potentially leading to therapeutic effects in conditions where peptide regulation is disrupted.
-== Mechanism of Action ==
+==Potential Therapeutic Uses==
+Velneperit has been investigated for its potential use in treating conditions such as [[chronic pain]], [[hypertension]], and [[heart failure]]. The ability of Velneperit to modulate peptide levels makes it a candidate for these applications, although clinical trials are necessary to fully understand its efficacy and safety.
-Velneperit works by blocking the Y4 subtype of the neuropeptide Y receptor. [[Neuropeptide Y]] is a neurotransmitter that is involved in a variety of physiological processes, including appetite regulation. By blocking the Y4 receptor, Velneperit is thought to reduce appetite and promote weight loss.
+==Research and Development==
+Research on Velneperit has included preclinical studies and early-phase clinical trials. These studies aim to evaluate the pharmacokinetics, pharmacodynamics, and therapeutic potential of the compound. Results from these studies will determine the future development of Velneperit as a therapeutic agent.
-== Clinical Trials ==
+==Related Pages==
+* [[Neutral endopeptidase]]
+* [[Enkephalin]]
+* [[Pain management]]
-Velneperit has undergone several phases of [[clinical trials]]. In early trials, the drug showed promise in reducing body weight in obese patients. However, later trials revealed potential side effects, including nausea and abdominal discomfort. As of now, the drug has not been approved for use by any major regulatory bodies.
+==References==
+{{Reflist}}
-== Potential Applications ==
+[[Category:Chemical compounds]]
+[[Category:Pharmacology]]
-If approved, Velneperit could be used as a treatment for obesity. The drug could also potentially be used in the treatment of other conditions related to appetite regulation, such as [[eating disorders]].
+[[Category:Experimental drugs]]
-== See Also ==
-* [[Obesity]]
-* [[Neuropeptide Y]]
-* [[Clinical trials]]
-* [[Shionogi]]
-[[Category:Drugs]]
-[[Category:Obesity]]
-[[Category:Pharmaceuticals]]
-{{Pharma-stub}}